NO822643L - Fremgangsmaate til fremstilling av nye piperazinoner og deres anvendelse. - Google Patents

Fremgangsmaate til fremstilling av nye piperazinoner og deres anvendelse.

Info

Publication number
NO822643L
NO822643L NO822643A NO822643A NO822643L NO 822643 L NO822643 L NO 822643L NO 822643 A NO822643 A NO 822643A NO 822643 A NO822643 A NO 822643A NO 822643 L NO822643 L NO 822643L
Authority
NO
Norway
Prior art keywords
formula
residue
atoms
optionally substituted
means hydrogen
Prior art date
Application number
NO822643A
Other languages
English (en)
Norwegian (no)
Inventor
Rudi Beyerle
Heins Bender
Ursula Schindler
Rolf-Eberhard Nitz
Piero Antonio Martorana
Original Assignee
Cassella Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cassella Ag filed Critical Cassella Ag
Publication of NO822643L publication Critical patent/NO822643L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO822643A 1981-08-20 1982-08-02 Fremgangsmaate til fremstilling av nye piperazinoner og deres anvendelse. NO822643L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813132882 DE3132882A1 (de) 1981-08-20 1981-08-20 Neue piperazinone, ihre herstellung und verwendung

Publications (1)

Publication Number Publication Date
NO822643L true NO822643L (no) 1983-02-21

Family

ID=6139695

Family Applications (1)

Application Number Title Priority Date Filing Date
NO822643A NO822643L (no) 1981-08-20 1982-08-02 Fremgangsmaate til fremstilling av nye piperazinoner og deres anvendelse.

Country Status (23)

Country Link
US (1) US4598079A (pl)
EP (1) EP0072932B1 (pl)
JP (1) JPS5839673A (pl)
KR (1) KR880001622B1 (pl)
AT (1) ATE49596T1 (pl)
AU (1) AU556064B2 (pl)
BG (1) BG40142A3 (pl)
CA (1) CA1190227A (pl)
DD (1) DD206991A5 (pl)
DE (2) DE3132882A1 (pl)
DK (1) DK154765C (pl)
ES (1) ES515120A0 (pl)
FI (1) FI76325C (pl)
GR (1) GR78362B (pl)
HU (1) HU190696B (pl)
IL (1) IL66566A (pl)
NO (1) NO822643L (pl)
NZ (1) NZ200761A (pl)
PH (1) PH18447A (pl)
PL (1) PL139405B1 (pl)
PT (1) PT75444B (pl)
RO (1) RO85267B (pl)
ZA (1) ZA826031B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772705A (en) * 1985-07-25 1988-09-20 Pennwalt Corporation Processes for the preparation of trans 1,3,4,6,7,11b-hexahydro-7-aryl-2H-pyrazinol[2,1-a]isoquinolines
JPS62198671A (ja) * 1986-02-25 1987-09-02 Toyo Jozo Co Ltd 1−置換アルキル1,2−ジヒドロ−2−ピラジノン誘導体
DE3817198A1 (de) * 1988-05-20 1989-11-30 Cassella Ag Thienyl-piperazinone, ihre herstellung und verwendung
EP0411150B1 (en) * 1989-02-10 1996-11-27 Otsuka Pharmaceutical Co., Ltd. Indole derivatives, preparation thereof, and drug for preventing and treating nephritis containing same
US5238938A (en) * 1989-02-10 1993-08-24 Otsuka Pharmaceutical Co., Ltd. Indole derivatives
DE3908547A1 (de) * 1989-03-16 1990-09-20 Cassella Ag Thienylessigsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung sowie diese enthaltende arzneimittel und deren herstellung
DE3909379A1 (de) * 1989-03-22 1990-09-27 Cassella Ag Thienylpiperazine, verfahren zu ihrer herstellung, ihre verwendung sowie diese enthaltende arzneimittel und deren herstellung
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
US5883098A (en) * 1993-11-29 1999-03-16 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
DE4408530A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Verfahren zur Herstellung von Aminoethylglycin
AU693936B2 (en) 1994-08-25 1998-07-09 Merrell Pharmaceuticals Inc. Novel substituted piperidines useful for the treatment of allergic diseases
DK0815105T3 (da) * 1995-03-15 2002-01-21 Aventis Pharma Inc Heterocyklisk substituerede piperazinonderivater som tachykininreceptor-antagonister
JP3950170B2 (ja) * 1995-04-13 2007-07-25 アベンティス・ファーマスーティカルズ・インコーポレイテッド タキキニン受容体アンタゴニスト活性を有する新規な置換されたピペラジン誘導体
GB9510600D0 (en) * 1995-05-25 1995-07-19 Fujisawa Pharmaceutical Co Piperazine derivatives
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
CA2250587A1 (en) * 1996-04-03 1997-10-09 Christopher J. Dinsmore Inhibitors of farnesyl-protein transferase
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
IN190478B (pl) * 2000-11-07 2003-08-02 Sun Pharmaceutical Ind Ltd
AU2002326948A1 (en) * 2001-09-18 2003-04-01 Bristol-Myers Squibb Company Piperizinones as modulators of chemokine receptor activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1197089B (de) * 1962-01-25 1965-07-22 Richardson Merrell Inc Verfahren zur Herstellung von 2-Oxo-1, 2, 5, 6-tetrahydropyrazinen
US3390139A (en) * 1964-03-04 1966-03-11 Rohm & Haas Nu-vinyl-2-piperazinones
US3935214A (en) * 1968-07-26 1976-01-27 Donau-Pharmazie Gesellschaft M.B.H. 2-or 3 keto-3-or-2-phenyl-1,4-disubstituted piperazines
DE2438619A1 (de) * 1974-08-12 1976-02-26 Knoll Ag Verfahren zur herstellung von substituierten 2-ketopiperazin-derivaten
BE871310A (fr) * 1978-10-17 1979-04-17 Yoshitomi Pharmaceutical Nouveaux derives de la pyridazinone utilisables en therapeutique comme agents anti-thrombotiques et anti-hypertenseurs.

Also Published As

Publication number Publication date
FI822698A0 (fi) 1982-08-02
RO85267B (ro) 1984-10-30
IL66566A0 (en) 1982-12-31
AU556064B2 (en) 1986-10-23
PT75444A (de) 1982-09-01
ES8305739A1 (es) 1983-05-01
DK154765B (da) 1988-12-19
DE3280088D1 (de) 1990-02-22
PH18447A (en) 1985-07-08
ATE49596T1 (de) 1990-02-15
IL66566A (en) 1985-12-31
GR78362B (pl) 1984-09-26
DK342382A (da) 1983-02-21
EP0072932A2 (de) 1983-03-02
JPS5839673A (ja) 1983-03-08
RO85267A (ro) 1984-09-29
ZA826031B (en) 1983-07-27
DK154765C (da) 1989-05-16
EP0072932B1 (de) 1990-01-17
PT75444B (de) 1985-01-04
KR840001158A (ko) 1984-03-28
AU8742282A (en) 1983-02-24
DD206991A5 (de) 1984-02-15
KR880001622B1 (ko) 1988-09-02
EP0072932A3 (en) 1984-03-21
BG40142A3 (en) 1986-10-15
HU190696B (en) 1986-10-28
US4598079A (en) 1986-07-01
ES515120A0 (es) 1983-05-01
FI76325C (fi) 1988-10-10
FI822698L (fi) 1983-02-21
DE3132882A1 (de) 1983-03-03
NZ200761A (en) 1985-04-30
CA1190227A (en) 1985-07-09
PL139405B1 (en) 1987-01-31
FI76325B (fi) 1988-06-30
PL237952A1 (en) 1983-03-14

Similar Documents

Publication Publication Date Title
NO822643L (no) Fremgangsmaate til fremstilling av nye piperazinoner og deres anvendelse.
SU1140687A3 (ru) Способ получени карбостирильных производных или их фармацевтически приемлемых солей с кислотами
AU769465B2 (en) Heterocyclic compounds and methods to treat cardiac failure and other disorders
US3466287A (en) 1-((3-indolyl)-lower-alkyl)-4-substituted piperazines
US4059621A (en) Substituted benzamido propanolamines
NO118219B (pl)
NO764299L (pl)
DK145260B (da) Analogifremgangsmaade til fremstilling af 4-acylamino-phenyl-ethanolaminer eller syreadditionssalte heraf
DK151017B (da) Analogifremgangsmaade til fremstiiling af substituerede n-(4-indolyl-piperidino-alkyl)-benzimidazoloner eller fysiologisk acceptable syreadditionssalte deraf
DE2825906A1 (de) 3-(pyrazol-1'-yl)-pyridazinderivate, solche enthaltende arzneimittel und verfahren zur herstellung derselben
DE2060816A1 (de) Piperidinderivate
US4148796A (en) γ-Piperidinobutyrophenones
BG64559B1 (bg) Метод за получаване на 5-{4-[2-(n-метил-n-(2-пиридил)амино)-етокси]бензил}-2,4-тиазолидиндион
DD149069A5 (de) Verfahren zur herstellung neuer piperidinopropylerivate
DE2737630C2 (pl)
NO833217L (no) Isokinolinderivater, fremgangsmaate til deres fremstilling, farmasoeytiske preparater paa basis av disse forbindelser og deres anvendelse
PL191633B1 (pl) Pochodne indolu i kompozycja farmaceutyczna zawierająca pochodną indolu
NO810870L (no) Fremgangsmaate til fremstilling av pyrimidylkinazoliner
DE3132915A1 (de) 1,5-diphenylpyrazolin-3-on-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPS6112912B2 (pl)
DK169406B1 (da) Hydroxyalkoxy-4-phenylpropylindolforbindelser, deres fremstilling samt lægemidler med indhold deraf
US4112092A (en) 1-Naphthylmethyl-4-(thiazolyl-2)-piperazines
US4201723A (en) Diamine-benzophenones and a process for the preparation thereof
US3562294A (en) Indolyl-2-amino-2-methylpropanones
CH644125A5 (de) Benzo-as-triazin-derivate und verfahren zur herstellung derselben.